This Week in European MedTech and HealthTech: 20th March 2026

European HealthTech this week is defined by EU‑level regulatory moves (MDR/IVDR, AI Act/AI in healthcare guidance, HTA), plus a pivot in funding towards validation‑stage digital health and AI rather than early‑stage experiments.

EU regulation and policy

The Commission’s 2026 “Health Package” is moving forward with revisions to MDR/IVDR to ease bottlenecks: more predictable conformity assessments, a codified Helsinki procedure for borderline products, and risk‑based rather than fixed certificate validity.

EU‑level work continues on integrating AI Act obligations with MDR/IVDR so high‑risk medical AI can use a single sectoral conformity route instead of duplicated certification.

The AI Act is now in force and DG SANTE has updated its AI‑in‑healthcare page, reiterating requirements around risk management, data quality, transparency and human oversight for high‑risk medical AI systems.

EU HTA machinery is live, with joint clinical assessments ramping up and more MedTech expected in the 2026 pipeline, shaping what “HTA‑ready” evidence will look like for digital and AI‑enabled devices.

Market and ecosystem signals

Commentary this month frames 2026 as a “Great Rationalisation” in European HealthTech/MedTech: the end of cheap capital and regulatory ambiguity, replaced by industrial rigor, enforcement and financial discipline.

Analysis of digital health maturity shows wide variance in teleconsultation use and EHR access between member states, with WHO experts stressing that robust EHR infrastructure is a prerequisite for scalable digital health services.

Industry fora like health.tech Basel and Masters of Digital 2026 are positioning the ecosystem as moving from pilots to execution, with focus on AI deployment, prevention systems and digital clinical trials.

Funding and grants

Within the Horizon Europe 2026–27 work programme, a substantial part of a €14bn R&I envelope is earmarked for health and digital technologies, reinforcing medium‑term support for AI, data and platform‑driven health innovation.

Global Health EDCTP3 has opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV, climate‑linked infectious disease), all with clear digital and clinical innovation angles.

A new Global Health EDCTP3/Horizon call offers up to €2.25m per project (total €18m) for digital innovation and AI health research in Sub‑Saharan Africa, which will be relevant for EU‑Africa digital health collaborations and data platforms.

EIT Health has launched its 2026 Innovation Validation Call, co‑funding up to 50% of late‑stage digital/data/AI health projects (max €850k) to accelerate clinical validation, regulatory approval and market launch.

In parallel, national and private schemes like Switzerland’s Future of Health Grant 2026 continue to target telemedicine, analytics, preventive care and digital therapeutics.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]

>>>>

European MedTech this week is being driven by the EU “Health Package” around MDR/IVDR, a Brussels high‑level conference on devices, and a tightening, consolidation‑oriented market narrative.

EU regulatory and policy moves

The Commission’s 2026 Health Package advances an MDR/IVDR “reset” with more predictable conformity assessments, a codified Helsinki procedure for borderline products, and risk‑based certificate validity instead of a fixed 5‑year term.

EU HTA machinery is now live, and more MedTech is expected to enter joint clinical assessments in 2026, which raises the evidentiary bar for pan‑EU market access dossiers.

Work continues on aligning AI Act “high‑risk” obligations with MDR/IVDR so that high‑risk medical AI can follow a single sectoral route rather than duplicated certification, with core AI Act obligations expected to apply around August 2026.

Devices, innovation and procurement agenda

On 16 March 2026, the Commission is hosting a high‑level conference in Brussels on “Medical Devices: Innovation and Patient Safety,” covering conformity assessment predictability, expert panels’ role in clinical evidence, and guidance for breakthrough technologies.

New EU proposals are set to overhaul procurement rules for MedTech and diagnostics, with potential shifts in pricing, value‑based award criteria and access conditions for both incumbents and innovators.

MedTech Europe has also highlighted recent developments in EU–US trade measures and participation in the HERA Industrial Cooperation Forum, underlining industrial‑policy and supply‑security angles for the sector.

Funding, capital and consolidation

Global Health EDCTP3 has opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV/co‑morbidities, climate‑linked infectious disease), explicitly supporting digital/clinical innovation and data‑/AI‑heavy platforms that often bundle devices, diagnostics and software.

Within the Horizon Europe 2026–27 work programme, a substantial part of a €14bn R&I envelope is earmarked for health and digital technologies, backing mid‑term innovation in AI‑enabled devices and diagnostics.

Analysts describe 2026 as a “Great Rationalisation” for European MedTech/HealthTech, with MDR/IVDR‑driven costs and complexity forcing portfolio pruning and pushing consolidation, often with hardware incumbents acquiring software/data capabilities to build “compliance moats.”

Ecosystem and internationalisation

European AI‑driven MedTech companies are increasingly designing offerings around US reimbursement and institutional contracting, as showcased at CES 2026, reflecting a push to scale outside Europe while EU reforms work through.

Events like MedTech Exchange Europe (Berlin), health.tech 2026 (Basel), and the upcoming MedTech Forum 2026 (Stockholm) are centering on AI‑powered digital transformation, regulatory complexity and cost pressure, and how to operationalise EHDS‑aligned data and SaMD strategies.

European Digital HealthTech‑linked meetings (e.g. Athens Digital Health Week, EDHC 2026) are being used as coordination points on EHDS, SaMD/AI adoption and market entry, which directly affects device‑plus‑software and diagnostics business models.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]